Dulaglutide (Trulicity) studies: 418 papers with results
Page 2 of 9
- Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC · Hypertension (Dallas, Tex. : 1979) · 2014
Randomized controlled trial · 6 results
- Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
Miyagawa J · Diabetes, obesity & metabolism · 2015
Randomized controlled trial · 15 results
- Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y · Endocrine journal · 2014
Randomized controlled trial · 12 results
- Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Frias JP · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 12 results
- Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
Xiao X · Journal of diabetes investigation · 2020
Randomized controlled trial · 5 results
- Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.
Baur F · BMJ nutrition, prevention & health · 2023
Randomized controlled trial · 4 results
- Effects of dulaglutide on alcohol consumption during smoking cessation.
Probst L · JCI insight · 2023
Randomized controlled trial · 2 results
- Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
Takase T · Journal of diabetes investigation · 2019
Randomized controlled trial · 10 results
- Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.
Beck J · European journal of preventive cardiology · 2025
Randomized controlled trial · 7 results
- A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
Zoungas S · The lancet. Diabetes & endocrinology · 2026
Randomized controlled trial · 19 results
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC · Lancet (London, England) · 2019
Randomized controlled trial · 4 results
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Gerstein HC · The lancet. Diabetes & endocrinology · 2020
Randomized controlled trial · 6 results
- Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
Osonoi T · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 16 results
- Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
Kaneko S · Endocrine journal · 2017
Randomized controlled trial · 11 results
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
Pirro V · The Journal of clinical endocrinology and metabolism · 2022
Randomized controlled trial · 11 results
- Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
Bonora E · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 8 results
- Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
Tuttle KR · Kidney360 · 2021
Randomized controlled trial · 3 results
- Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Yu M · Clinical therapeutics · 2017
Randomized controlled trial · 8 results
- Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Rosenstock J · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 17 results
- Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.
Gentilella R · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
Randomized controlled trial · 9 results
- Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Suzuki S · Health and quality of life outcomes · 2017
Randomized controlled trial · 4 results
- Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
Onishi Y · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
Randomized controlled trial · 8 results
- Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
Frias J · Journal of the Endocrine Society · 2021
Randomized controlled trial · 28 results
- Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Branch KRH · European journal of heart failure · 2022
Randomized controlled trial · 5 results
- Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR · Cardiovascular diabetology · 2020
Randomized controlled trial · 2 results
- Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.
Raubenheimer PJ · Diabetes, obesity & metabolism · 2022
Randomized controlled trial · 3 results
- Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
Romera I · Journal of diabetes and its complications · 2020
Randomized controlled trial · 3 results
- Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Mari A · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 7 results
- Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
Hamamoto Y · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
Randomized controlled trial · 40 results
- A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 9 results
- Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
Li YM · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
Randomized controlled trial · 11 results
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.
Umpierrez GE · Diabetes, obesity & metabolism · 2011
Randomized controlled trial · 12 results
- Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
Zhou Y · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Randomized controlled trial · 12 results
- Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
Ishii H · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
Randomized controlled trial · 9 results
- Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.
Su Y · Frontiers in endocrinology · 2023
Randomized controlled trial · 15 results
- Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients.
Fushimi N · Journal of diabetes investigation · 2020
Randomized controlled trial · 8 results
- Effects of GLP-1 receptor agonists on copeptin in euvolemic participants.
Leibnitz S · European journal of endocrinology · 2026
Randomized controlled trial · 4 results
- Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
Vukajlovic T · The Journal of clinical endocrinology and metabolism · 2022
Randomized controlled trial · 7 results
- Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
Yabe D · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 12 results
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T · The lancet. Diabetes & endocrinology · 2025
Randomized controlled trial · 18 results
- Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.
Xie D · Cardiovascular diabetology · 2022
Randomized controlled trial · 14 results
- The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
Wang J · BioMed research international · 2019
Randomized controlled trial · 19 results
- Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study.
Lengsfeld S · EBioMedicine · 2024
Randomized controlled trial · 6 results
- A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
Li H · Journal of diabetes research · 2019
Randomized controlled trial · 15 results
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers.
Winzeler B · The Journal of clinical endocrinology and metabolism · 2019
Randomized controlled trial · 6 results
- Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
Cai TT · BioMed research international · 2021
Randomized controlled trial · 3 results
- Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
Kubota M · Cureus · 2023
Randomized controlled trial · 7 results
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
Jiang H · Nature communications · 2022
Randomized controlled trial · 13 results
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S · Lancet (London, England) · 2022
Randomized controlled trial · 13 results
- The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Wilson JM · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 21 results